Skip to main content
S&P 5007,809.74+0.57%DOW51,648.23+0.81%NASDAQ27,349.54+0.57%BTC$82,674.00+2.30%ETH$2,488.73+3.01%GOLD$4,216.10+1.42%OIL$91.25-0.26%
Smart Investors Daily
SID Premium
FE

NASDAQ · FENC

Fennec Pharmaceuticals Inc.

Healthcare · Biotechnology

$10.63

Up+$0.05 (+0.47%)

Updated Oct 9, 2026, 4:18 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
206.35M
P/E ratio
-30.1
Dividend yield
0.00%
52-week range
$5.65 – $13.25
Volume
87.24K
Avg. volume
118.26K

Price performance · FENC

FENC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

FENC closed at $10.63 after 21 trading sessions, down 5.93% for the selected period.

Last close
$10.63
Period change
-5.93%
Period low
$10.20
Period high
$11.30
Daily close
View OHLC price history
FENC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$10.27$10.695$10.245$10.6387.24K
Oct 7, 2026$10.21$10.66$10.0778$10.36130.79K
Oct 6, 2026$10.64$10.66$10.15$10.3599.08K
Oct 5, 2026$10.18$10.655$10.01$10.62118.02K
Oct 2, 2026$10.46$10.49$10.03$10.20136.44K
Oct 1, 2026$10.58$10.65$10.14$10.33130.15K
Sep 30, 2026$10.81$10.83$10.41$10.65149.21K
Sep 29, 2026$10.99$11.11$10.64$10.80117.74K
Sep 28, 2026$10.54$11.06$10.07$10.95210.22K
Sep 25, 2026$10.53$10.81$10.51$10.605105.07K
Sep 24, 2026$10.41$10.626$10.21$10.62103.54K
Sep 23, 2026$11.01$11.01$10.5001$10.51141.63K
Sep 22, 2026$11.00$11.31$10.845$11.0191.7K
Sep 21, 2026$10.63$10.94$10.43$10.91132.86K
Sep 18, 2026$10.78$10.88$10.585$10.62126.31K
Sep 17, 2026$10.74$10.99$10.74$10.78128.58K
Sep 16, 2026$10.64$10.96$10.515$10.55170.33K
Sep 15, 2026$10.60$10.65$10.135$10.64253.7K
Sep 14, 2026$10.94$11.11$10.68$10.72186.01K
Sep 11, 2026$11.30$11.51$10.85$10.96249.93K
Sep 10, 2026$11.51$11.7299$11.271$11.30171.68K

Latest FENC news

The latest Smart Investors Daily articles mentioning FENC.

Stock researchCompany · Overview

FENC research

Overview

Company profile and research snapshot.

Company profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.00
Implied upside
—
Analysts
—
FENC recent ratings
DateFirmRatingTarget
Sep 9, 2026HC Wainwright & Co.Buy—
Aug 12, 2026WedbushOutperform—
Aug 12, 2026B. Riley SecuritiesBuy—
May 22, 2026HC Wainwright & Co.Buy—
Apr 16, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK® Administration Interva

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By